Skip to main content
US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
Screen a stock
TERMINAL
RT

RTSNStock

Healthcare

$10.51 last close 2026-11-20
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment RTSN's does — no target price to set, unlike a price alert.

Sharia status
NOT COMPLIANT
Per our in-house ratio engine
0 of 3 pass our own screen — 4 of 7 could not be computed
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No trade setup shown — a stock that isn't cleanly Sharia-compliant never gets a bullish verdict here.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure1 of 5 timeframes bullish · 26.1% aligned
VWAPPrice below VWAP ($11.49)
VolumeRelative volume 6.1× the 20-day average
Momentum10-day rate of change -4.8%

RTSN is currently considered not halal (non-compliant), per our in-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.

⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.

434 other Healthcare stocks pass this same screen. See compliant Healthcare stocks →

Market & analysts
Price target
$51.67
+391.6% · 3 analysts
Institutional own.
21.1%
of shares
Momentum (10d)
-4.8%
rate of change
SMC grade
D · 42
26.1% aligned
D · 42
SMC grade — 26.1% timeframe alignment
-4.8%
Rate of change (10d)
$51.67
Price target (+391.6%) · 3 analysts
21.1%
Institutional ownership

How the status reached this point

Non-compliant · status tracked since Nov 17, 2026

No change to RTSN’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.

Read once a day from the status this page publishes, last on Nov 21, 2026. The per-methodology record is under “What changed, and when” in the in-house research.

Free email, sent when our compliance re-scan finds a change.

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap stored with these figures ($108.4M); this record does not say which day it was fetched, so no estimate for today is made from it.

Business activity: not screened

We have not screened this company's line of business, so these ratios say nothing about whether what it does is permissible.

AAOIFI Unverified⚠️ a figure this standard needs was not available, so it could not be scored — the rows below show what was and was not computed 2 of 3 computed, both pass
RatioValueThresholdResult
Interest-bearing debt 0.00% 30.00% Pass(30.0pp buffer)
Interest-bearing investments 8.48% 30.00% Pass(21.5pp buffer)
Non-permissible income
total revenue not reported; interest income not reported; revenue is $0 - ratio undefined
not available 5.00% Unverified
Usmani Fail 4 of 5 computed, 3 pass, 1 fails
RatioValueThresholdResult
Interest-bearing debt 0.00% 33.00% Pass(33.0pp buffer)
Interest-bearing investments 64.95% 33.00% Fail(32.0pp over)
Non-liquid assets 35.05% at least 20.00% Pass(15.0pp above the floor)
Non-permissible income
total revenue not reported; interest income not reported; revenue is $0 - ratio undefined
not available 5.00% Unverified
Net liquid assets per share $2.5M under mkt cap $108.4M Pass
MSCI Fail 3 of 4 computed, 1 passes, 2 fail
RatioValueThresholdResult
Interest-bearing debt 0.00% 33.33% Pass(33.3pp buffer)
Cash + interest-bearing securities 64.95% 33.33% Fail(31.6pp over)
Accounts receivable 64.95% 33.33% Fail(31.6pp over)
Non-permissible income
total revenue not reported; interest income not reported; revenue is $0 - ratio undefined
not available 5.00% Unverified
FTSE Fail 3 of 4 computed, 1 passes, 2 fail
RatioValueThresholdResult
Interest-bearing debt 0.00% 33.33% Pass(33.3pp buffer)
Cash + interest-bearing securities 64.95% 33.33% Fail(31.6pp over)
Accounts receivable 64.95% 50.00% Fail(15.0pp over)
Non-permissible income
total revenue not reported; interest income not reported; revenue is $0 - ratio undefined
not available 5.00% Unverified

ℹ️ Dow Jones Islamic Market, MSCI M-Series, S&P Shariah divide by a trailing-average market cap (24- or 36-month) rather than today's. That price history is not collected for non-US listings, so these are reported as unverified — it reflects a missing input on our side, not anything about the company.

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

Usmani (% of total assets)nonliquid assets ratio · floor 15.0pts
Usmani (% of total assets)debt ratio 33.0pts
MSCI Islamic Index (% of total assets)debt ratio 33.3pts
Usmani (% of total assets)investments ratio 32.0pts
MSCI Islamic Index (% of total assets)cash and interest ratio 31.6pts
MSCI Islamic Index (% of total assets)receivables ratio 31.6pts

The numbers the ratios are built from

Read from RTSN's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period not measured — —
Interest-bearing debtShort and long-term borrowings $0 2026-09-30 no debt tag reported in 3+ years (treated as $0)
Cash and interest-bearing securitiesCash, equivalents and marketable securities $9.2M 2026-09-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
Total assetsBalance sheet total $14.1M 2026-09-30 Assets
Market capDenominator for AAOIFI $108.4M live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series not measured — —
24-month average market capDenominator for Dow Jones Islamic Market not measured — —
Non-permissible revenueInterest and excluded income not measured — —

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet: Quarterly report (10-Q) filed 2026-11-18, period ended 2026-09-30. Screened 2026-11-20.

  • Total assets$14.1M
    Assets · period ended 2026-09-30 · 10-Q filed 2026-11-18
  • Interest-bearing debt$0
    no debt tag reported in 3+ years (treated as $0) · balance sheet as of 2026-09-30 · no filing link for this figure
  • Cash and interest-bearing securities$9.2M
    CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · period ended 2026-09-30 · 10-Q filed 2026-11-18
  • Receivables$0
    no receivables tag reported in 3+ years (treated as $0) · balance sheet as of 2026-09-30 · no filing link for this figure
  • Market cap$108.4M
    Market quote passed in by the screen (Finnhub company profile; Yahoo Finance where Finnhub has none), 2026-11-20 · not a filing figure, so no link

2 reported values cited from 1 SEC filing, read from SEC's XBRL company facts when this symbol was screened. A link opens the filing's index on EDGAR.

What changed, and when

Verdict history for RTSN. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-11-20 Unverified → Fail filing re-screen

Tracked since 2026-09-07.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B —
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

16.3314.8813.4211.9710.512026-10-092026-10-302026-11-20

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
11.13
S2
11.87
S1
12.44
PIVOT
13.18
R1
13.75
R2
14.49
R3
15.06

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
6.08 – 14.94
±42.11% from 10.51, made 2026-11-22 · resolves 2026-11-29
STRONG SELL
from 13 indicators
78.6% of our last 30385 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 53.9% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
13 indicators
OscillatorsSTRONG SELL
1 buy · 3 neutral · 2 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 7 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)45.30NEUTRAL
Stochastic %K (14)25.96NEUTRAL
CCI (20)-105.75BUY
Williams %R (14)-74.04NEUTRAL
ROC (10)-4.80SELL
Momentum (10)-0.53SELL
EMA (10)12.04SELL
SMA (10)12.14SELL
EMA (20)12.35SELL
SMA (20)12.09SELL
EMA (30)12.56SELL
SMA (30)12.70SELL
EMA (50)12.63SELL

About RTSN

Healthcare · Biotechnology

Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The Company operates as a single operating and reportable segment focused on the development of treatments for hypertension and cardiovascular disease. The company was incorporated in 2023 and is headquartered in Falls Church, Virginia.

retensionpharmaceuticals.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily RANGING 31
⏰ 4H BULLISH 19
🕐 1H RANGING 77
⏱ 15-Min BEARISH 130
⏲ 5-Min BEARISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-4.8%
Rate of change (10d)
6.1×
Volume vs its 20-day average

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-17 · Asset managers net 895049 (-19081)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.